首页> 美国卫生研究院文献>Gynecologic Oncology Research and Practice >Adenocarcinoma of Mullerian origin: review of pathogenesis molecular biology and emerging treatment paradigms
【2h】

Adenocarcinoma of Mullerian origin: review of pathogenesis molecular biology and emerging treatment paradigms

机译:穆勒起源的腺癌:发病机制分子生物学和新兴治疗范例的回顾

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two primary histologic groups that encompass the standard histologic subtypes. Recent data suggest that these groupings no longer accurately reflect our knowledge surrounding these cancers. In this review, we propose that epithelial ovarian, tubal, and peritoneal carcinomas represent a spectrum of disease that originates in the Mullerian compartment. We will discuss the incidence, classification, origin, molecular determinants, and pathologic analysis of these cancers that support the conclusion they should be collectively referred to as adenocarcinomas of Mullerian origin. As our understanding of the molecular and pathologic profiling of adenocarcinomas of Mullerian origin advances, we anticipate treatment paradigms will shift towards genomic driven therapeutic interventions.
机译:传统上,上皮性卵巢癌,输卵管癌和腹膜癌被视为起源,发病机制,临床特征和结果不同的独立实体。另外,先前的卵巢癌分类系统已经提出了两个主要的组织学类型,包括标准的组织学亚型。最近的数据表明,这些分组不再准确反映我们对这些癌症的了解。在这篇综述中,我们提出上皮性卵巢癌,输卵管癌和腹膜癌代表了一系列起源于穆勒室的疾病。我们将讨论这些癌症的发生率,分类,起源,分子决定因素和病理学分析,这些结论支持将它们统称为穆勒起源的腺癌的结论。随着我们对Mullerian起源的腺癌的分子和病​​理学谱的理解的发展,我们预计治疗范例将转向基因组驱动的治疗干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号